Appeals court invalidates $1.2 billion fine against Gilead Sciences

Gilead logo

The U.S. Court of Appeals for the Federal Circuit tossed a $1.2 billion fine against Gilead Sciences after invalidating portions of a Memorial Sloan Kettering Cancer Center patent licensed to a Bristol Myers Squibb subsidiary.

The patent was the basis for the previous ruling against Foster City, Calif.–based Gilead, which related to patent infringement claims associated with Yescarta, a CAR-T immunotherapy developed by Gilead’s Kite Pharma subsidiary. The Bristol Myers Squibb unit Juno Therapeutics had developed a similar treatment.

In a legal opinion representing a unanimous three-judge decision, Chief U.S. Circuit Judge Kimberly Moore reasoned that the portions of the Memorial Kettering Cancer Center patent lacked adequate details.

In 2019, a jury concluded that Kite Pharma had infringed on the patent and awarded the Memorial Sloan Kettering…

Read more
  • 0

Paige pathology viewer lands FDA clearance

AI-aided pathology company Paige today announced it received FDA clearance for its FullFocus digital pathology image viewer for the purpose of primary diagnosis.

This clearance allows in vitro diagnostic (IVD) use of FullFocus with the FDA-authorized Philips Ultra Fast Scanner and paves the way for IVD use of FullFocus with additional IVD whole slide imaging (WSI) scanners, according to the New York-based company.

The foundation for the FullFocus viewer was created and validated at Memorial Sloan Kettering Cancer Center (MSK) to allow researchers and pathologists to view and navigate digital images of surgical pathology slides acquired on all major commercial brands of WSI scanners. After refinement based on 18 months of daily use for retrospective slide review by dozens of practicing pathologists at MSK, the viewer was further enhanced by Paige to meet the performance requirements for IVD use, with accurate color reproducibility, optimized viewing speeds and a…

Read more
  • 0

Paige pulls in another $20m in Series B round

AI-pathology company Paige today announced it received an additional $15 million from Goldman Sachs, bringing its Series B funding round to $70 million.

The previously announced round also included $5 million from and Healthcare Venture Partners, which added to its previous $10 million investment. Goldman Sachs had also invested $5 million in April.

New York-based Paige, a spinout from Memorial Sloan Kettering Cancer Center, said it will use this new capital to improve cancer pathology workflows and to work with biopharma companies to create custom diagnostic and clinical trial solutions.

“We appreciate the continued recognition and support we’ve received from Goldman Sachs as we gain traction and prove early results in the clinical and biopharma space,” said Paige CEO Leo Grady in a news release. “This new funding will help ensure that the Paige platform and our advanced computational pathology products will drive the next generation of pathology and im…

Read more
  • 0